NCT06243770

Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants

A Phase 1, Randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of intravenously (IV) administered mRNA-0184 under different infusion conditions.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	mRNA-0184	Intravenous infusion

Timeline

• Start date: 2024-02-16
• Primary completion: 2025-06-12
• Completion: 2025-06-12
• First posted: 2024-02-06
• Last updated: 2025-08-01

Locations

1 site across 1 country: Australia

Regulatory

• FDA-regulated drug study